Takeda Pharmaceutical Co Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Welcome to the JPMorgan Healthcare Conference. I'm Seiji Wakao, Japan Pharma analyst in JPMorgan. And it's my pleasure to introduce Christophe Weber, CEO of Takeda, and welcome him to the conference.
The presentation will be followed directly by Q&A. Audience can submit questions anytime by using the ask a question on the (inaudible) conference book, resend your questions.
With that, let me turn it over to Christophe.
Thank you, Wakao San, and hello, everyone. It's my great pleasure to be with you today even if remotely. I'm really delighted to update you on Takeda and our progress, especially because this year 2021 will be clearly a very inflection -- a very special inflection year for Takeda.
I'll go through the presentation, and I will say the slide numbers, so that you can follow. On Slide #2, the traditional notice regarding forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |